| Literature DB >> 34689425 |
Kenichi Koga1, Takeshi Ishihara2, Yohei Doi1,3, Ryota Suzuki4, Masakazu Komatsu4, Kosei Abe5, Takahiro Tanaka5, Ryuji Iwaki6, Hiroyuki Hashi6, Akira Sugawara1.
Abstract
INTRODUCTION: Cell-free and concentrated ascites reinfusion therapy (CART) is used for the treatment of diuretic-resistant ascites. An increase in circuit pressure and clogging of the filtration membrane often occur in CART for malignant ascites.Entities:
Keywords: ascites; cancer; filtration; membranes; scanning electron microscopy
Mesh:
Substances:
Year: 2021 PMID: 34689425 PMCID: PMC9297898 DOI: 10.1111/1744-9987.13747
Source DB: PubMed Journal: Ther Apher Dial ISSN: 1744-9979 Impact factor: 2.195
FIGURE 1Circuit settings. (A) Two filtration methods are used to filter the original ascites samples at 50 mL/min. (B) After the first filtration, the filtration membrane is reverse washed using 500 mL of saline at 40 kPa. The filtered ascites is combined with 1000 mL of wash fluid and filtered again using the same circuit at the same treatment rate as the initial filtration. The circuit pressure was measured at the entry and exit sites of the filtration membrane, and the transmembrane pressure (TMP) was calculated
FIGURE 2Ultrastructural observation of the filtration membrane cartridge. (A) The locations of the nine observation points on the filtration membrane cartridge are shown. (B) Representative images of the filtration membrane cartridge used to filter ascites are shown. The filtration membrane cartridge used to filter ascites from a patient with liver cirrhosis (case 1) showed no deposition on the filter membrane. The filtration membrane cartridges from a patient with (C) papillary renal cell carcinoma (case 11), (D) uterine cancer (case 13), and (E) ovarian cancer (case 9) were found to have deposits of cells, fibrin, and cells and fibrin, respectively (original magnification 1000×)
Characteristics of patients and original ascites samples
| Hepatic ascites | Malignant ascites |
| |
|---|---|---|---|
| Number of patients | 4 | 17 | |
| Age (years), mean (SD) | 56.5 (53.8–57.8) | 71 (66.0–76.5) | <0.05 |
| Sex (male), No. (%) | 4 (100) | 3 (17.7) | <0.01 |
| Types of cancer, No. (%) | |||
| Ovary | ‐ | 6 (35.3) | |
| Gastrointestinal | ‐ | 5 (29.4) | |
| Pancreas | ‐ | 1 (5.9) | |
| Gallbladder and bile duct | ‐ | 1 (5.9) | |
| Lung | ‐ | 1 (5.9) | |
| Bladder | ‐ | 1 (5.9) | |
| Uterine | ‐ | 1 (5.9) | |
| Ascitic volume (mL) | 3489 (2813–3542) | 2488 (1425–3671) | N.S. |
| Bloody ascites, No. (%) | 3 (75.0) | 10 (58.8) | N.S. |
| Total protein (g/dL) | 1.65 (1.0–2.9) | 3.6 (2.8–4.5) | <0.05 |
| Albumin (g/dL) | 0.75 (0.6–1.6) | 1.8 (1.2–2.2) | 0.054 |
| IL‐6 (pg/mL) | 1895 (1125–7442) | 4910 (1980–15 800) | 0.15 |
| IgG (mg/dL) | 436 (258–528) | 718 (527–1140) | <0.05 |
| IgA (mg/dL) | 77 (54–119) | 122 (68–181) | N.S. |
| IgM (mg/dL) | 16 (15–18) | 26 (18–41) | <0.05 |
| FDP (μg/mL) | 392 (190–1203) | 890 (448–1880) | 0.20 |
| Haptoglobin (mg/dL) | 15 (10–69) | 61 (40–109) | 0.13 |
| α1‐antitrypsin (mg/dL) | 41 (31–146) | 158 (96–227) | <0.05 |
| WBC (102/μL) | 1.3 (0.9–2.4) | 1.0 (0.5–3.3) | N.S. |
| RBC (104/μL) | 1 (0.3–1.8) | 1 (0–2.0) | N.S. |
| Plt (102/μL) | 0.2 (0.1–0.4) | 0.3 (0.2–0.4) | N.S. |
Note: Continuous variables are presented as medians and interquartile ranges and categorical variables are presented as number (%).
Abbreviations: FDP, fibrinogen/fibrin degradation products; IgA, immunoglobulin A; IgG, immunoglobulin G; IgM, immunoglobulin M; IL‐6, interleukin‐6; N.S., not significant; Plt, platelets; RBC, red blood cells; WBC, white blood cells.
FIGURE 3Circuit pressures in ascites from a patient with liver cirrhosis and ascites from a patient with papillary renal cell carcinoma. The transmembrane pressure (TMP) of the filtration membrane in during the filtration of ascites from a patient with liver cirrhosis (case 2) is shown in panels (A–C) and that of the ascites from a patient with papillary renal cell carcinoma (case 11) is shown in panels (D–F) Case 2 is representative of the hepatic ascites cases included in this study. Panels (A) and (D) represent the first filtration, (B) and (E) represent the reverse wash, and (C) and (F) represent the second filtration. An increased pressure was observed during filtration in case 11
Composition of original ascites samples among samples that resulted in cellular deposits and those that did not
| No cellular deposition | Cellular deposition |
| |
|---|---|---|---|
| Number of samples (%) | 14 (82.3) | 3 (17.6) | |
| Ascitic volume (mL) | 2530 (1479–3564) | 1720 (1235–4039) | N.S. |
| Bloody ascites, No. (%) | 7 (50) | 3 (100) | 0.11 |
| Total protein (g/dL) | 3.5 (2.5–4.0) | 4.3 (4.1–4.9) | 0.10 |
| Albumin (g/dL) | 1.7 (1.1–2.1) | 2.3 (1.4–2.7) | N.S. |
| IL‐6 (pg/mL) | 5620 (3193–16 650) | 1690 (716–15 200) | N.S. |
| IgG (mg/dL) | 699 (509–1139) | 718 (653–1825) | N.S. |
| IgA (mg/dL) | 108 (54–152) | 234 (134–273) | <0.05 |
| IgM (mg/dL) | 28 (17–42) | 26 (21–34) | N.S. |
| FDP (μg/mL) | 909 (376–1823) | 725 (548–2000) | N.S. |
| Haptoglobin (mg/dL) | 60 (32–122) | 68 (61–98) | N.S. |
| α1‐antitrypsin (mg/dL) | 149 (97–237) | 158 (60–218) | N.S. |
| WBC (102/μL) | 0.8 (0.4–2.1) | 7.8 (2.5–8.5) | <0.05 |
| RBC (104/μL) | 1.0 (0–1.0) | 14.0 (2.0–61.0) | <0.05 |
| Plt (102/μL) | 0.25 (0.1–0.3) | 0.6 (0.4–0.6) | <0.05 |
Note: Continuous variables are presented as medians and interquartile ranges and categorical variables are presented as number (%).
Abbreviations: FDP, fibrinogen/fibrin degradation products; IgA, immunoglobulin A; IgG, immunoglobulin G; IgM, immunoglobulin M; IL‐6, interleukin‐6; N.S., not significant; Plt, platelets; RBC, red blood cells; WBC, white blood cells.
Composition of original ascites samples among samples that resulted in fibrin deposits and those that did not
| No fibrin deposition | Fibrin deposition |
| |
|---|---|---|---|
| Number of patients (%) | 11 (67.4) | 6 (35.2) | |
| Ascitic volume (mL) | 3250 (1316–4039) | 1932 (1458–2900) | N.S. |
| Bloody ascites, No. (%) | 7 (63.6) | 3 (50) | N.S. |
| Total protein (g/dL) | 3.3 (2.2–4.1) | 4.3 (3.4–5.3) | 0.11 |
| Albumin (g/dL) | 1.4 (1.1–2.1) | 2 0.1 (1.5–2.7) | 0.16 |
| IL‐6 (pg/mL) | 3500 (1640–4910) | 15 800 (12 083–18 300) | <0.01 |
| IgG (mg/dL) | 653 (504–1143) | 732 (630–1293) | N.S. |
| IgA (mg/dL) | 122 (50–144) | 147 (85.8–207) | N.S. |
| IgM (mg/dL) | 26.0 (17–38) | 27.5 (20–48) | N.S. |
| FDP (μg/mL) | 548 (369–890) | 2005 (945–2410) | <0.005 |
| Haptoglobin (mg/dL) | 55 (10–68) | 109 (82–155) | <0.05 |
| α1‐antitrypsin (mg/dL) | 105 (54–168) | 239 (204–254) | <0.005 |
| WBC (102/μL) | 1.1 (0.5–3.1) | 0.5 (0.0–8.8) | 0.16 |
| RBC (104/μL) | 0.3 (0.2–0.5) | 0.2 (0.1–0.4) | N.S. |
| Plt (102/μL) | 0.3 (0.2–0.5) | 0.3 (0.1–0.4) | N.S. |
Note: Continuous variables are presented as medians and interquartile ranges and categorical variables are presented as number (%).
Abbreviations: FDP, fibrinogen/fibrin degradation products; IgA, immunoglobulin A; IgG, immunoglobulin G; IgM, immunoglobulin M; IL‐6, interleukin‐6; N.S., not significant; Plt, platelets; RBC, red blood cells; WBC, white blood cells.
FIGURE 4Proteome analyses. The results of the proteome analyses in two samples from the hepatic ascites group (cases 1 and 2) and 10 samples from the malignant ascites group (cases 5–14) are shown
FIGURE 5Bloody ascites. The bloody ascites samples from a patient with liver cirrhosis (case 2) and a patient with papillary renal cell carcinoma (case 11) are shown. The bloody ascites was more apparent in case 11, which had a higher concentration of red blood cells